Article (Scientific journals)
Gliptines, securite cardio-vasculaire et insuffisance cardiaque: le point apres l'etude TECOS.
Scheen, Andre
2015In Revue Médicale Suisse, 11 (483), p. 1526-31
Peer Reviewed verified by ORBi
 

Files


Full Text
RMS_tecos.pdf
Publisher postprint (532.67 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Abstract :
[en] The cardiovascular safety of dipeptidyl peptidase-4 inhibitors (gliptins) has been well studied. Favourable effects of these oral antidiabetic agents have been reported in meta-analyses of phase II-III randomised controlled trials. Three large prospective trials, which were specifically designed to investigate cardiovascular safety, showed non-inferiority of saxagliptin (SAVOR-TIMI 53), alogliptin (EXA-MINE) and sitagliptin (TECOS) versus placebo as far as major cardiovascular events are concerned, including mortality. The suspected increase in the rate of hospitalisation due to congestive heart failure reported in SAVOR-TIMI 53 was neither found in EXAMINE nor recently confirmed in TECOS. Direct comparative trials, evaluating not only safety but also efficacy, with other oral antidiabetic medications would be of major interest.
Disciplines :
Cardiovascular & respiratory systems
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, Andre  ;  Université de Liège - ULiège
Language :
French
Title :
Gliptines, securite cardio-vasculaire et insuffisance cardiaque: le point apres l'etude TECOS.
Alternative titles :
[en] Gliptins, cardiovascular safety and congestive heart failure: state of the art after TECOS
Publication date :
2015
Journal title :
Revue Médicale Suisse
ISSN :
1660-9379
Publisher :
Medecine et Hygiène, Switzerland
Special issue title :
Thérapeutique
Volume :
11
Issue :
483
Pages :
1526-31
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 30 October 2015

Statistics


Number of views
333 (2 by ULiège)
Number of downloads
656 (1 by ULiège)

Scopus citations®
 
10
Scopus citations®
without self-citations
0

Bibliography


Similar publications



Contact ORBi